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Abstract 
Cancer metastasis is facilitated by cell-cell interactions between cancer cells and 
endothelial cells in distant tissues. In addition, cancer cell interactions with platelets and 
leukocytes contribute to cancer cell adhesion, extravasation, and the establishment of 
metastatic lesions. Selectins are carbohydrate-binding molecules that bind to sialylated, 
fucosylated glycan structures, and are found on endothelial cells, platelets and 
leukocytes. There are three members of the selectin family: P-selectin expressed on 
activated platelets and endothelial cells, L-selectin present on leukocytes and E-selectin 
expressed on activated endothelial cells. Besides the accepted roles of selectins in 
physiological processes, such as inflammation, immune response and hemostasis, there 
is accumulating evidence for the potential of selectins to contribute to a number of 
pathophysiological processes, including cancer metastasis. Cancer cell interactions with 
selectins are possible due to a frequent presence of carbohydrate determinants – 
selectin ligands on the cell surface of tumor cells from various type of cancer. The 
degree of selectin ligand expression by cancer cells is well correlated with metastasis 
and poor prognosis for cancer patients. Initial adhesion events of cancer cells facilitated 
by selectins result in activation of integrins, release of chemokines and are possibly 
associated with the formation of permissive metastatic microenvironment. While E-
selectin has been evaluated as one of the initiating adhesion events during metastasis, it 
is becoming apparent that P-selectin and L-selectin mediated interactions significantly 
contribute to this process as well. In this review we discuss the current evidence for 
selectins as potential facilitators of metastasis.  
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Introduction 
Hematogenous metastasis of cancer consists of several steps enabling cancer cells to 
intravasate, to survive in the blood circulation and to adhere to the vessels, eventually 
extravasating and establishing new metastatic lesions. Interactions of intravascular 
cancer cells with blood constituents (platelets, leukocytes) can modulate their capacity 
to adhere to endothelium in distant organs thereby facilitating metastasis. This process 
of cancer cell adhesion and seeding to specific vascular beds appears to be a rate 
limiting step in cancer metastasis. It is well accepted that malignant transformation is 
associated with abnormal glycosylation resulting in presentation of altered carbohydrate 
structures. Enhanced expression of sialyl Lewisx and sialyl Lewisa structures is 
frequently associated with cancer progression and poor prognosis [1]. At the same time, 
these carbohydrates are recognized selectin ligands. Selectins are vascular cell 
adhesion molecules involved in interactions of leukocytes, platelets and endothelium. 
Due to the temporal and spatial presence of selectins during hematogeneous 
dissemination and early organ colonization, interactions with carbohydrate ligands on 
cancer cells can be expected. Studies from several laboratories suggest that metastatic 
cancer cells exploit similar mechanisms as used by leukocytes for adhesion and 
extravasation through endothelium that may contribute to metastasis [2, 3]. Recent 
evidence also indicates that selectin-mediated interactions may contribute to formation 
of a permissive microenvironment for metastasis [4]. 
 
Selectins – vascular cell adhesion molecules 
Selectins were identified to be the key adhesion molecules that mediate leukocyte 
trafficking and hemostasis, soon after their cloning and characterization [5-7]. 
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Subsequently, selectins were implicated in many human diseases including cancer [3, 7-
10]. Selectins are type-I transmembrane glycoproteins consisting of an extracellular C-
type lectin domain, an EGF domain, two to nine consensus repeats, a transmembrane 
domain and a cytoplasmic tail [5]. L-selectin is constitutively expressed on all myeloid 
cells, on naïve T-cells and some activated memory T-cells [5, 11]. Activation of 
leukocytes leads to a rapid loss of L-selectin from their cell surfaces due to a proteolytic 
cleavage [7].  P-selectin is constitutively expressed in endothelial cells of the lung and 
the choroid plexus, megakaryocytes, thrombocytes and is stored within Weibel-Pallade 
bodies of endothelial cells or alpha-granules of platelets, respectively [5, 6]. P-selectin is 
rapidly presented on the surface of activated endothelial cells or platelets by means of 
exocytosis of storage granules and their fusion with the cell membrane [12-14]. E-
selectin is expressed exclusively by endothelial cells, mainly in response to local 
activation [5]. Constitutive expression of E-selectin has been detected in the skin and 
parts of bone marrow microvasculature [15]. In most vessels de novo synthesis and 
expression of E-selectin can be induced within two to six hours in response to 
inflammatory stimuli (e.g. TNF-α and IL-1β) or disturbed blood flow [5, 16]. Expression of 
P- and E-selectin is tightly regulated during homeostasis, thereby ensuring spatial and 
temporal adhesion/recruitment of leukocytes. However, E-selectin may remain up-
regulated in the endothelium in areas of chronic inflammation [17, 18].  
 
Selectin ligands 
Selectin-based adhesion is mediated by heterotypic interactions of their C-type lectin 
domain with glycan-bearing ligands. Functional selectin ligands require post-
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translational modification of scaffold proteins by glycosyltransferases and 
sulfotransferases [5, 19-21]. The minimal recognition motif for all selectins is the sialyl-
Lewisx sLex and its isomer sialyl-Lewisa (sLea) tetrasaccharide that is synthesized by 
α1,3-Fucosyltransferases IV or VII, α2,3-Sialyltransferases, β1,4-Galactosyltranferases 
and N-Acetyl-Glucosaminyltransferases [5, 21, 22]. Efficient selectin-binding to 
carbohydrates usually requires a glycoprotein scaffold that facilitates the presentation of 
several selectin ligands in clusters [5, 20]. P-selectin glycoprotein ligand-1 (PSGL-1) is 
the best characterized ligand, which is concentrated on the tips of microvilli on leukocyte 
cell surfaces. All three selectins bind to PSGL-1, while potent binding of P- and L-
selectin to PSGL-1 is facilitated by additional sulfation of the amino-terminal part of the 
protein [5, 6]. Although leukocytes express a number of different selectin ligands, e.g. 
CD44 [23], or E-selectin ligand-1 (ESL-1) [24], PSGL-1 is the main physiological ligand 
for P-selectin [5, 6]. L-selectin mediates the trafficking of leukocytes, in particular 
lymphocytes through binding to peripheral node addressins (PNAds) that are endothelial 
glycoproteins [21]. E-selectin binds to a number of ligands, including PSGL-1, ESL-1, 
CD44, CD43, β2-integrins, and L-selectin [5, 25-29]. Mucins are major carriers of altered 
glycosylation that occur during progression of epithelial cancers - carcinomas. Mucins 
are high-molecular-weight molecules containing a protein core substituted with a large 
number of O-linked glycan structures [9, 30]. Major alterations are an enhanced 
expression of sLex/a, or Tn and sialyl-Tn antigen structures on mucins [31]. Carcinoma 
mucins expressing sLex/a structures are major selectin ligands on cancer cells. In 
addition to mucins, several other selectin ligands on cancer cells have been described 
including CD24, CD44, death-receptor 3, ESL-1 and PSGL-1 [32-35]. However, the in 
vivo relevance of these ligands remains to be determined [24]. Finally, P- and L-selectin, 
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but not E-selectin can bind to sulfated glycans including heparin, heparin sulfate, 
fucoidan and sulfated glycolipids in a calcium-independent manner [20, 36]. The large 
variety of different carbohydrate structures recognized by selectins indicates that the 
lectin domain of selectins recognize a certain carbohydrate “patch” that can be 
generated in different ways [20]. 
 
Roles of selectins health and disease 
The characterization of selectin and selectin ligand deficient mice has provided 
information about the physiological functions of selectins in inflammation, immune 
response, wound repair and hemostasis [37-41]. These findings have been further 
confirmed in mice deficient in selectin ligands, e.g. FucT-VII, Core 2 
glucosaminyltransferase, or PSGL-1 [42-45]. Extravasation of leukocytes comprises 
sequential steps including tethering of leukocytes on endothelial cells, fast and slow 
rolling, firm adhesion and trans- or para-endothelial migration [46, 47]. Selectins mediate 
the initial tethering and are critically involved in the transition from fast to slow rolling 
before leukocytes firmly adhere to endothelial cells [5, 6, 47]. Transition from fast to slow 
rolling requires activation of integrins that is in part supported by selectin or PSGL-1 
outside-in signaling [48, 49]. Given the central role in leukocyte extravasation and 
trafficking, selectins are involved in innate and adaptive immune responses and this 
topic is extensively covered elsewhere [5, 21, 47]. Importantly, cell homing studies in 
mice showed that adhesion of leukocytes differs between organs and types of 
inflammation [7, 50].  
P-selectin on platelets is involved in thrombus formation during hemostasis [51, 52]. The 
procoagulant activity of P-selectin is mainly explained by its role in the formation of 
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leukocyte derived microparticles containing tissue factor, the key inducer of the extrinsic 
coagulation cascade [52, 53]. Moreover, PSGL-1 on platelets could enhance 
interactions between them and mediate binding of platelets to P- and E-selectin on 
activated endothelial cells, thus influencing hemostasis [54]. 
Acute systemic inflammatory responses to infectious or toxic stimulants and trauma are 
uncontrolled inflammatory, life threatening events that can lead to SIRS (systemic 
inflammatory response syndrome), sepsis and eventually to multi-organ failure [55]. 
Selectins are involved in acute organ damage during sepsis by mediating the 
recruitment of myeloid cells [56]. In different disease models, P- or E-selectin deficient 
mice are protected from acute inflammation and tissue damage [57, 58]. L-selectin 
deficiency also decreases leukocyte recruitment to sites of acute inflammation [59]. 
Inhibition of E- or P-selectin by antibodies or heparin showed significantly reduced 
disseminated intravascular coagulation and mortality in an experimental septic shock 
model [60].  
Chronic inflammation plays a key role in atherosclerosis, the main cause of morbidity 
and mortality in developed nations [61]. Recruitment of inflammatory cells during 
progression of the atherosclerotic lesion is partially selectin dependent [61]. The 
absence of P-selectin reduces atherosclerotic lesions due to reduced monocyte 
recruitment [62]. Monocyte recruitment during atherogenesis is facilitated by P-selectin 
on activated platelets adherent on the endothelium [63]. P-selectin mediated rolling of 
platelets on activated endothelial cells further supports progression of atherosclerotic 
lesions [64]. Atherosclerosis is partly decreased by the absence of E-selectin [65]. 
Finally, L-selectin was recently implicated in atherosclerosis by enhancing lymphocyte 
recruitment [66]. 
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Selectin interactions beyond cell adhesion 
Selectin-mediated interactions facilitate not only cell adhesion, but may also participate 
in signal transduction, thereby affecting cell migration and activation of other adhesion 
molecules including integrins [47-49, 67]. Selectin engagement can trigger signals in 
both the selectin-expressing and the ligand-expressing cells [68, 69]. While the signaling 
pathways for selectins are just being revealed, leukocyte extravasation represents the 
best described selectin-initiated signaling pathway [47]. Binding of L-selectin can 
activate leukocytes and affect the cytoskeleton trough interactions between the 
cytoplasmic tail of L-selectin with α-actinin, ezrin/radixin/moesin (ERM) family proteins, 
calmodulin, increase of intracellular calcium and induction of the p38 mitogen-activated 
kinase pathway [49, 70-74]. L-selectin mediated activation of neutrophils can lead to the 
production of reactive oxygen species, TNF-α, interleukin-8 and integrins, including 
CD11b [49, 75]. Monocytes can be activated by the engagement of PSGL-1 on their 
surfaces by P-selectin [76]. P-selectin binding to PSGL-1 induces signaling that 
activates integrins through the Src kinase family, Nef-associated factor 1 and 
phosphoinositide-3-OH-kinases [48, 77, 78]. The cytoplasmic tail of PSGL-1 also 
interacts via ERM proteins with the cytoskeleton and the spleen tyrosine kinase (SYK) 
that may transmit signals [79, 80]. There is also evidence that the engagement of P-
selectin transmits signals to endothelial cells and platelets, while the mechanism 
remains unclear [49]. E-selectin binding to PSGL-1 activates β2 integrins through the 
SYK and Src kinase pathway that is required for initiation of neutrophil slow rolling [81]. 
E-selectin itself can transduce signals into endothelial cells through p38 and p42/p44 
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MAPK pathway [69]. Finally, selectin binding to cell-surface-bound mucins may also 
transmit signals into cancer cells during cancer progression, e.g. by enhancing growth 
factor receptor signaling [30, 82].  
 
Selectins and cancer progression 
How cancer cells metastasize is still not completely understood. Experimental evidence 
and observational clinical studies suggest that cancer cell seeding requires specific 
interactions with the local microenvironment that lead to tumor cell adhesion or 
mechanical arrest, survival, extravasation and outgrowth in target organs. As described 
above, the majority of cancer cells, carcinoma cells in particular, express elevated levels 
of selectin ligands that are associated with poor prognosis [reviewed in 1, 10, 31]. 
Selectin-mediated interactions of cancer cell binding to and activation of leukocytes, 
platelets and endothelial cells provide a mechanistic explanation for this poor prognosis 
(Figure 1) [83-85]. Cell-cell interactions with leukocytes, platelets and endothelium 
appear to be critical for metastatic progression. Parallels between selectin-mediated 
leukocyte recruitment and extravasation during inflammation, and adhesion/arrest and 
extravasation of cancer cells during metastasis has been observed in different models 
(Figure 1) [2, 8, 9]. Moreover, recent findings suggest that selectins mainly support 
tumor progression via the cooption of inflammatory pathways [4]. Finally, selectins are 
strongly involved in coagulation abnormalities often observed in cancer patients, further 
affecting the progression of the disease [10, 86, 87].  
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E-selectin during cancer progression 
E-selectin is a major adhesion receptor on endothelial cells for leukocytes and has been 
repeatedly shown to support metastasis in vivo [88, 89]. E-selectin has been 
investigated as a mediator of the process by which cancer cells adhere/arrest in the 
microvasculature during metastasis [3, 90, 91]. The presence of E-selectin ligands on 
cancer cells correlates with enhanced adhesion to activated endothelium [92-95]. E-
selectin ligands on cancer cells have been found to be mostly mucins [96], yet several 
unique E-selectin ligands have been recently identified on cancer cells, including dead 
receptor-3 and a specific CD44 glycoform [33, 34]. E-selectin binding of death receptor 3 
or other ligands on cancer cells has been shown to increase survival during metastasis 
[34, 97]. Recent work provides evidence that E-selectin binding to cancer cells may alter 
the gene expression profile of cancer cells [97]. Furthermore, E-selectin has been 
shown to regulate endothelial transmigration through activation of p38 and ERK AP 
kinases [98, 99]. Since distinct E-selectin ligands on neutrophils have been shown to 
induce different reactions [24], it can be expected that the nature of E-selectin ligands 
presented on cancer cells may induce specific processes both in endothelial cells as 
well as in cancer cells.  
E-selectin is expressed on activated endothelial cells and has been shown to be 
upregulated during metastatic colonization of the liver [88, 89]. Downregulation of E-
selectin expression or inhibition of E-selectin function resulted in attenuation of 
experimental liver metastasis. In a transgenic mouse model over-expressing E-selectin 
in the liver, metastases were redirected to this organ, thus confirming the role of E-
selectin in this process [100]. In an experimental metastasis model where mice were 
injected with IL-1, co-injection of cancer cells with soluble E-selectin probe led to a 
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reduction of metastasis in the lungs [93]. However, induced E-selectin expression by a 
high cytokine dose does not reflect the natural process of metastatic lung colonization. 
We recently demonstrated that E-selectin is disposable in a model of experimental lung 
metastasis [101]. These findings probably reflect organ specific differences in the 
colonization process and different requirements for selectin-mediated interactions 
depending on the primary tumor and the metastatic organ. Nevertheless, in vivo 
evidence for cancer cell rolling on activated endothelium mediated through E-selectin 
that leads to metastatic colonization requires further investigation. 
 
P-selectin during cancer progression 
The close “relationship” of circulating cancer cells with platelets is one of the factors 
contributing to cancer progression [14, 102-104]. Substantial evidence indicates that 
platelets interact with circulating cancer cells, thereby creating tumor microemboli that 
may facilitate arrest in distant organs and subsequently promote interactions with 
endothelium [102, 103]. Evidence that platelets support metastasis initially came from 
models of experimentally induced thrombocytopenia [105, 106]. Likewise, platelet-
deficient mice lacking Nf-E2 showed reduced metastasis [107]. The underlying 
mechanism for the initiation of platelet-cancer cell thrombi formation remains to be 
defined. However, experimental evidence strongly indicates that platelet P-selectin 
contributes to the thrombi formation and aids colonization of cancer cells in the lungs 
[84, 108]. Platelet aggregates on cancer cells lodged in the vasculature was virtually 
absent in P-selectin deficient mice and was associated with a limited initial seeding of 
cancer cells to the lungs [108]. Platelets were shown to bind to cancer cells through 
carcinoma cell surface mucins in a P-selectin dependent manner. Removal of cell 
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surface mucins from cancer cells prior to intravenous injection resulted in attenuation of 
metastasis [108]. Bone marrow transplantation experiments in P-selectin deficient mice 
have shown that endothelial P-selectin also contributes to metastasis [109]. 
Furthermore, inhibition of P-selectin-mediated interactions of platelets with cancer cell 
ligands by heparin treatment attenuates cancer metastasis in mice [108, 109].   
Patients suffering from advanced cancer are at high risk for thromboembolic events, a 
finding initially described by Trousseau [87]. The particular association between 
thrombotic diathesis and mucinous carcinomas led to hypothesis that mucins, carrying 
selectin ligands, trigger this syndrome. Intravenous injection of purified carcinoma 
mucins led to a rapid generation of platelet-rich microthrombi [87]. Interestingly, in P-
selectin but also L-selectin deficient mice the microthrombi generation was markedly 
diminished, indicating the involvement of platelet P-selectin and leukocytes in thrombotic 
events accompanying cancer progression.  
 
L-selectin during cancer progression 
Initial studies focused on the potential role of L-selectin on tumor cells by homing to L-
selectin ligand expressing tissues [110, 111]. Transgenic ectopic expression of L-
selectin in a spontaneous mouse carcinoma model facilitated lymph node metastasis 
[110]. However, naturally occurring L-selectin on a B-cell lymphoma cell line was not 
associated with enhanced lymph node metastasis [111]. 
Inflammation is a key component of the tumor microenvironment and leukocytes have 
been shown to promote both primary tumor growth as well as metastatic dissemination 
[112, 113]. Leukocyte responses to cancer are not unique, and have many parallels with 
the inflammatory response to infection and during wound healing [112, 114]. 
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Contribution of leukocytes to metastasis largely depends on spatial and temporal 
stimulation that is defined by the microenvironment and cancer cells [112, 114, 115]. L-
selectin-mediated leukocyte recruitment to locally activated endothelial cells is one 
possible means that may be exploited by cancer cells. The contribution of L-selectin to 
metastasis was analyzed in L-selectin deficient mice [83, 85]. The absence of L-selectin 
led to attenuation of metastasis. This finding actively implicates leukocytes to the 
process of metastasis, since L-selectin expression is restricted to leukocytes [83]. L-
selectin mediated recruitment of leukocytes to tumor emboli was found to occur 
subsequent to P-selectin-mediated platelet-cancer cell complex formation [85, 101]. 
These observations suggest that L-selectin mediates recruitment and adhesion of 
leukocytes within the microenvironment of metastasizing cancer cells, either with the 
tumor thrombus itself or with the adjacent endothelium. Concomitantly, enhanced 
expression of L-selectin ligands around the cancer cell embolus correlated with the 
recruitment of leukocytes to the intravascular cancer cells, indicative of locally activated 
endothelium [85]. Leukocytes associated with cancer cells in the vasculature were 
identified as CD11b positive cells of myeloid origin (monocytes, neutrophils, or 
precursors). Further studies have shown that monocytes can directly increase 
transendothelial migration of cancer cells through L-selectin mediated interactions (L.B., 
manuscript in preparation). Thus, leukocytes may assist cancer cells in breaching the 
endothelial barrier at sites of intravascular arrest, thereby facilitating metastatic 
colonization [116]. 
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Selectins promote metastasis by shaping the metastatic niche 
There is sufficient experimental evidence that selectins mainly promote metastasis by 
facilitating heterotypic interactions between cancer cells and blood components 
including endothelial cells (Figure 2) [3, 10].  
After entering the bloodstream directly or via lymphatics, cancer cells are transported to 
distant organs, where they are arrested within the microvasculature (Figure 2a) [117, 
118].  Platelet-cancer cell association and the formation of a tumor embolus during the 
intravascular phase is thought to be a key step during metastatic dissemination and 
colonization (Figure 2b) [14, 102-104, 119]. Cancer patients with advanced, metastatic 
disease have increased serum levels of markers of platelet activation and a higher 
percentage of activated platelets, probably indicating platelet activation during 
metastatic spread [104, 120]. Whether cancer cell-platelet interactions are directly 
initiated after intravasation or after microvascular arrest of cancer cells remains unclear. 
In experimental metastasis models, formation of tumor emboli within the pulmonary 
microvasculature is observed rapidly after the injection of cancer cells (Figure 2b) [105, 
108]. Nevertheless, the proof for significant tumor cell emboli formation in cancer 
patients is hampered by pre-analytical treatment of blood samples with a considerable 
chance of introducing artifacts. Since the isolation methods for circulating cancer cells 
are becoming more standardized [121, 122], the isolation of circulating tumor emboli 
may become feasible. Primary activation of platelets by cancer cells in vivo is not yet 
completely understood, but abundant evidence indicates the involvement of tissue factor 
induced formation of thrombin and signaling through protease activated receptors (PAR) 
[123, 124]. In mice with platelets lacking PAR4, activation of platelets was strongly 
reduced and metastasis diminished [107]. Besides minor roles for GPIIb/IIIa and 
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GPIb/IX in aggregation of platelets on cancer cells [105, 125-127], tumor emboli 
formation mainly depends on P-selectin mediated interactions [108]. Platelets and tumor 
emboli formation may promote metastasis by various means including protection from 
immune-mediated clearance of cancer cells through NK-cells [128, 129], enhancement 
of microvascular arrest [127], cancer cell invasion through secretion of proteases [130, 
131], as well as enhanced angiogenesis and growth through the release of various 
cytokines such as PDGF and VEGF and bioactive lipids like lysophosphatidic acid  [14, 
104, 132]. We recently provided evidence that platelets promote metastatic colonization 
by supporting the formation of an inflammatory niche within the lung microvasculature 
[4]. P-selectin mediated interactions between cancer cells, platelets and neutrophils led 
to a local inflammatory activation of endothelial cells [4]. Platelets can support 
inflammatory activation by the release of cytokines and chemokines [13]. It is 
conceivable that the formation of a tumor embolus through P-selectin leads to locally 
increased levels of platelet cytokines and chemokines. Platelet aggregation and tumor 
emboli formation may additionally occlude microvessels and thus lead to hypoxic areas, 
promoting a local inflammatory reaction. Moreover, platelet aggregation on cancer cells 
induces and is perpetuated by the coagulation cascade, finally resulting in increased 
levels of thrombin and fibrin deposition [119]. Thrombin itself can activate cancer cells 
and the local endothelium through PAR signaling [119, 124], thereby potentially 
enhancing local inflammation. 
The inflammatory microenvironment that is generated by tumor-embolus formation 
activates the adjacent endothelium and recruitment of leukocytes (Figure 2c). Markers of 
endothelial cell activation and inflammation are up-regulated during the first hours after 
microvascular arrest of cancer cells in models of experimental liver and lung metastasis 
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[88, 101, 133]. Endothelial cell activation markers such as soluble E-selectin and ICAM-
1 detected in plasma are elevated in cancer patients with advanced disease [134]. 
Reduction of endothelial cell activation in experimental models was associated with 
decreased metastasis [135, 136]. Activated endothelial cells further support local 
inflammatory activation and formation of a metastatic niche, mainly by mediating the 
recruitment of leukocytes. Recruitment and activation of inflammatory cells, in particular 
myeloid cells are associated with enhanced metastatic colonization [4, 85, 116, 137, 
138]. Selectin mediated interactions facilitate the recruitment of leukocytes to the 
metastatic microenvironment [4, 83, 85]. L-selectin mediated interactions were 
demonstrated to be essential for the recruitment of neutrophils and monocytes in an 
experimental model of metastasis [83, 85]. Interactions of L-selectin with a yet 
unidentified FucT VII dependent ligand on activated endothelial cells contribute to 
recruitment of leukocytes [85]. Furthermore, selectin dependent interactions between 
cancer cells, platelets and neutrophils led to the up-regulation of endothelial CCL5 and 
subsequent recruitment of monocytes to the metastatic microenvironment [4]. Inhibition 
of CCL5 and subsequently reduced monocyte recruitment attenuated metastasis [4]. 
Myeloid cells may support metastatic colonization by local immune-suppression, cancer 
cell survival, invasion and extravasation (Figure 2d) [114, 139, 140]. Monocytes and 
descendant macrophages were recently shown to facilitate lung colonization by 
enhancing extravasation [116]. L-selectin dependent recruitment of monocytes can 
directly increase vascular permeability and transendothelial migration of cancer cells 
(L.B., manuscript in preparation). E-selectin has also been shown to contribute to the 
extravasation process [91].  
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Many studies linking selectins to the metastatic process have utilized experimental 
metastasis models. A limitation of direct intravascular injection of cancer cells is the 
absence of a pre-metastatic niche. The pre-metastatic niche was first identified in mouse 
models of spontaneous metastasis and has subsequently been shown to be present in 
cancer patients [141-143]. Myeloid precursor cells are mobilized and recruited to specific 
locations by the primary tumor in an endocrine dependent manner [141-143].  Thereby 
myeloid cells can shape the local microenvironment in order to make it permissive for 
arriving cancer cells [141-143]. The role of selectins in the formation of the pre-
metastatic niche, however, remains largely elusive and necessitates further studies and 
validation in human cancer patients.  
 
Selectin-inhibitors as anti-metastatic therapeutics 
The expression and involvement of selectins during inflammation, immune response and 
cancer led to the rationale that inhibitors of selectins could be used as anti-inflammatory, 
immune-modulating, and anti-cancer agents and several types of inhibitors were 
developed over the past years [7, 144]. Selectin inhibitors can be divided into glycan-
based molecules, small molecules including glycomimetics, soluble forms of ligands and 
antibodies either targeting selectins or their ligands. The first tested inhibitor was a 
sialyl-Lewisx tetrasaccharide that could target all selectins. However the low affinity, high 
production costs and unfavorable pharmacokinetics made it not suitable for further 
development [7]. Glycometabolic inhibitors have been developed that indirectly reduce 
the production of selectin ligands by inhibition of relevant glycosyltransferases, in 
particular O-glycosylation of mucins and fucosyltransferases [144, 145]. Treatment of 
cancer cells with a disaccharide-based inhibitor that serves as a decoy for the glycan 
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synthesis led to reduction of cancer cell-associated sLex structures and subsequently to 
attenuation of metastasis [146, 147]. A recombinant soluble form of PSGL-1 was shown 
to inhibit the rolling of leukocytes in vivo, and prevents inflammation in different modes 
of inflammation [144, 148, 149]. However, clinical trials were discontinued partly due to 
high production costs [7]. Small molecules or glycomimetics including bimosiamose 
(TBC-1269), cylexin (CY1503) and efomycine M that inhibit selectins were tested in 
models of ischemia-reperfusion injury, psoriasis and asthma and to some extent 
evaluated in clinical trials [144, 150-152]. Selectin blocking antibodies that successfully 
passed preclinical evaluation were examined in patients with psoriasis, reperfusion 
injury or cerebral ischemia with no or only minimal clinical effect [151].  
Heparin is a glycosaminoglycan exclusively expressed and stored in mast cells and 
consists of N- and O-sulfated alternating galactosamine/glucosamine and glucoronic 
acid/iduronic acid moieties [153]. Heparin and fractionated low molecular weight 
heparins are clinically used for their anti-coagulant activity via antithrombin III and the 
pentasaccharide sequence for this effect is well characterized [153]. Moreover, 
unfractionated heparin and some clinically used low molecular heparins bind to P- and 
L-selectins and inhibit their function [108, 154, 155]. However, not all low molecular 
weight heparins show inhibitory activity on selectins, indicating that selectin binding to 
heparin requires a specific properties independent of anticoagulant activity [155, 156]. 
Indeed, chemically modified heparins with minimal anticoagulant activity but retained its 
selectin inhibitory activity efficiently attenuated experimental metastasis [10, 108, 157-
159]. Besides inhibition of selectins, heparins probably improve survival by influencing 
heparanase activity, growth factor signaling and inhibition of different cell adhesion 
19 
 
molecules including integrins [36]. In clinical trials, heparins are associated with a better 
survival of patients [160].  
Selectins are mainly implicated in hematogenous metastasis during the intravascular 
phase of cancer cells. Based on the above described mechanism, heparin inhibition of 
P- and L-selectin should be applied immediately following initial cancer diagnosis until a 
period of time (e.g. a few weeks) after surgical removal of the primary tumor [161]. 
Moreover, the demonstrated implication of selectins in the metastatic process warrants 
the application of selectin inhibitors to patients with a local tumor stage in order to 
prevent dissemination. Since selectins are crucial for homeostasis, it is unlikely that 
prolonged treatment will be feasible. Based on the proposed treatment window 
encompassing about two months, the specific inhibition of one or two selectins should 
be well tollerated. Interestingly, there is precedence for the prolonged inhibition of P-
selectin. Therapeutic doses of heparin efficiently inhibit P-selectin and also L-selectin, 
therefore cancer patients treated with heparin as an anticoagulant inadvertently 
achieved significant P-selectin inhibition [154]. Clinical trials are currently ongoing that 
evaluate the use of low molecular weight heparins after surgery of localized tumors in 
addition to adjuvant systemic treatment (e.g. NCT00475098, NCT00967148). Finally, 
modified heparins with a selective effect on selectin inhibition or other inhibitors of 
selectins require further examination in preclinical models and testing in early clinical 
trials. 
 
Conflict of interest  
None 
 
20 
 
Acknowledgements 
We apologize to all colleagues whose important work could not be cited due to space 
limitations. This work was supported by grants from Swiss National Foundation 
#3100A0-116295 (to L.B.) 
 
References 
 
1. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in 
cancer metastasis and angiogenesis. Cancer Sci 2004;95:377-384. 
2. Krause T, Turner GA. Are selectins involved in metastasis? Clin Exp Metastasis 1999;17:183-192. 
3. Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev 
2008;27:19-30. 
4. Läubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces 
expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 
2009;114:4583-4591. 
5. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996;88:3259-
3287. 
6. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 
2002;14:581-586. 
7. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003;9:263-268. 
8. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J 
1997;14:585-591. 
9. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of 
cancer. Glycoconj J 1997;14:577-584. 
10. Borsig L, Stevenson JL, Varki A: Heparin in Cancer: Role of Selectin Interactions. In Cancer-
Associated Thrombosis Edited by Khorana AA, Francis CW. New York: Informa Healthcare; 2007: 
97-113. 
11. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes 
with distinct homing potentials and effector functions. Nature 1999;401:708-712. 
12. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in 
physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-3561. 
13. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and 
cardiovascular disease. Circ Res 2007;100:27-40. 
21 
 
14. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 
2008;8:1247-1255. 
15. Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, Means TK, et al. In vivo imaging of specialized 
bone marrow endothelial microdomains for tumour engraftment. Nature 2005;435:969-973. 
16. Morigi M, Zoja C, Figliuzzi M, Foppolo M, Micheletti G, Bontempelli M, et al. Fluid shear stress 
modulates surface expression of adhesion molecules by endothelial cells. Blood 1995;85:1696-
1703. 
17. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule 
for skin-homing T cells. Nature 1991;349:796-799. 
18. Keelan ET, Licence ST, Peters AM, Binns RM, Haskard DO. Characterization of E-selectin 
expression in vivo with use of a radiolabeled monoclonal antibody. Am J Physiol 1994;266:H278-
290. 
19. Lowe JB. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr Opin Cell 
Biol 2003;15:531-538. 
20. Varki A. Selectin ligands: will the real ones please stand up? J Clin Invest 1997;99:158-162. 
21. Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol 
2004;22:129-156. 
22. Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking. Immunol Rev 
2009;230:97-113. 
23. Katayama Y, Hidalgo A, Chang J, Peired A, Frenette PS. CD44 is a physiological E-selectin 
ligand on neutrophils. J Exp Med 2005;201:1183-1189. 
24. Hidalgo A, Peired AJ, Wild MK, Vestweber D, Frenette PS. Complete identification of E-selectin 
ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity 
2007;26:477-489. 
25. Picker LJ, Warnock RA, Burns AR, Doerschuk CM, Berg EL, Butcher EC. The neutrophil selectin 
LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 
1991;66:921-933. 
26. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS. CD43 is a ligand for E-selectin on CLA+ human 
T cells. Blood 2006;107:1421-1426. 
27. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R. CD44 is a major E-selectin ligand on 
human hematopoietic progenitor cells. J Cell Biol 2001;153:1277-1286. 
28. Kotovuori P, Tontti E, Pigott R, Shepherd M, Kiso M, Hasegawa A, et al. The vascular E-selectin 
binds to the leukocyte integrins CD11/CD18. Glycobiology 1993;3:131-136. 
29. Steegmaier M, Levinovitz A, Isenmann S, Borges E, Lenter M, Kocher HP, et al. The E-selectin-
ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 1995;373:615-620. 
30. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat 
Rev Cancer 2004;4:45-60. 
22 
 
31. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in 
cancer. Glycoconj J 1997;14:569-576. 
32. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, et al. CD24, a mucin-type 
glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-3395. 
33. Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and L-selectin ligand 
expressed on LS174T colon carcinoma cells. J Biol Chem 2006;281:13899-13905. 
34. Gout S, Morin C, Houle F, Huot J. Death receptor-3, a new E-Selectin counter-receptor that 
confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK 
MAPK activation. Cancer Res 2006;66:9117-9124. 
35. Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, et al. Identification of leukocyte 
E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic 
prostate tumor cells. Cancer Res 2005;65:5750-5760. 
36. Läubli H, Borsig L. Heparins attenuate cancer metastasis: are selectins the link? Cancer Invest 
2009;27:474-481. 
37. Robinson SD, Frenette PS, Rayburn H, Cummiskey M, Ullman-Cullere M, Wagner DD, et al. 
Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte 
recruitment. Proc Natl Acad Sci U S A 1999;96:11452-11457. 
38. Homeister JW, Zhang M, Frenette PS, Hynes RO, Wagner DD, Lowe JB, et al. Overlapping 
functions of E- and P-selectin in neutrophil recruitment during acute inflammation. Blood 
1998;92:2345-2352. 
39. Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, et al. Lymphocyte homing and 
leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1994;1:247-
260. 
40. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and 
extravasation are severely compromised in P selectin-deficient mice. Cell 1993;74:541-554. 
41. Labow MA, Norton CR, Rumberger JM, Lombard-Gillooly KM, Shuster DJ, Hubbard J, et al. 
Characterization of E-selectin-deficient mice: demonstration of overlapping function of the 
endothelial selectins. Immunity 1994;1:709-720. 
42. Xia L, Sperandio M, Yago T, McDaniel JM, Cummings RD, Pearson-White S, et al. P-selectin 
glycoprotein ligand-1-deficient mice have impaired leukocyte tethering to E-selectin under flow. J 
Clin Invest 2002;109:939-950. 
43. Maly P, Thall A, Petryniak B, Rogers CE, Smith PL, Marks RM, et al. The 
alpha(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, 
E-, and P-selectin ligand biosynthesis. Cell 1996;86:643-653. 
44. Homeister JW, Thall AD, Petryniak B, Maly P, Rogers CE, Smith PL, et al. The 
alpha(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-
dependent leukocyte recruitment and lymphocyte homing. Immunity 2001;15:115-126. 
23 
 
45. Sperandio M, Thatte A, Foy D, Ellies LG, Marth JD, Ley K. Severe impairment of leukocyte rolling 
in venules of core 2 glucosaminyltransferase-deficient mice. Blood 2001;97:3812-3819. 
46. Vestweber D. Regulation of endothelial cell contacts during leukocyte extravasation. Curr Opin 
Cell Biol 2002;14:587-593. 
47. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte 
adhesion cascade updated. Nat Rev Immunol 2007;7:678-689. 
48. Zarbock A, Muller H, Kuwano Y, Ley K. PSGL-1-dependent myeloid leukocyte activation. J 
Leukoc Biol 2009;86:1119-1124. 
49. Crockett-Torabi E. Selectins and mechanisms of signal transduction. J Leukoc Biol 1998;63:1-14. 
50. Wong J, Johnston B, Lee SS, Bullard DC, Smith CW, Beaudet AL, et al. A minimal role for 
selectins in the recruitment of leukocytes into the inflamed liver microvasculature. J Clin Invest 
1997;99:2782-2790. 
51. Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. Defects in 
hemostasis in P-selectin-deficient mice. Blood 1996;87:1238-1242. 
52. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb 
Haemost 2005;3:1590-1596. 
53. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, et al. Platelets adhere to and 
translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 
2000;96:3322-3328. 
54. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, et al. P-Selectin glycoprotein 
ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in 
vivo. J Exp Med 2000;191:1413-1422. 
55. Bone RC, Balk R, Slotman G, Maunder R, Silverman H, Hyers TM, et al. Adult respiratory distress 
syndrome. Sequence and importance of development of multiple organ failure. The Prostaglandin 
E1 Study Group. Chest 1992;101:320-326. 
56. Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in 
development of multiple organ failure in sepsis. Lancet 2006;368:157-169. 
57. Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/reperfusion-induced 
acute renal failure. FASEB J 2000;14:48-54. 
58. Mangell P, Mihaescu A, Wang Y, Schramm R, Jeppsson B, Thorlacius H. Critical role of P-
selectin-dependent leukocyte recruitment in endotoxin-induced intestinal barrier dysfunction in 
mice. Inflamm Res 2007;56:189-194. 
59. Tedder TF, Steeber DA, Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment 
into inflammatory sites. J Exp Med 1995;181:2259-2264. 
60. Norman KE, Cotter MJ, Stewart JB, Abbitt KB, Ali M, Wagner BE, et al. Combined anticoagulant 
and antiselectin treatments prevent lethal intravascular coagulation. Blood 2003;101:921-928. 
61. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 
2005;352:1685-1695. 
24 
 
62. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced 
atherosclerosis in ApoE-deficient mice. Circulation 2000;101:2290-2295. 
63. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. Circulating activated platelets 
exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-67. 
64. Rivera-Nieves J, Burcin TL, Olson TS, Morris MA, McDuffie M, Cominelli F, et al. Critical role of 
endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med 2006;203:907-917. 
65. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular 
adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in 
apolipoprotein E-deficient mice. J Exp Med 2000;191:189-194. 
66. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into 
the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. 
J Exp Med 2006;203:1273-1282. 
67. Juliano RL. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of 
integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu Rev Pharmacol 
Toxicol 2002;42:283-323. 
68. Yoshida M, Westlin WF, Wang N, Ingber DE, Rosenzweig A, Resnick N, et al. Leukocyte 
adhesion to vascular endothelium induces E-selectin linkage to the actin cytoskeleton. J Cell Biol 
1996;133:445-455. 
69. Simon SI, Hu Y, Vestweber D, Smith CW. Neutrophil tethering on E-selectin activates beta 2 
integrin binding to ICAM-1 through a mitogen-activated protein kinase signal transduction 
pathway. J Immunol 2000;164:4348-4358. 
70. Ivetic A, Deka J, Ridley A, Ager A. The cytoplasmic tail of L-selectin interacts with members of the 
Ezrin-Radixin-Moesin (ERM) family of proteins: cell activation-dependent binding of Moesin but 
not Ezrin. J Biol Chem 2002;277:2321-2329. 
71. Crockett-Torabi E, Sulenbarger B, Smith CW, Fantone JC. Activation of human neutrophils 
through L-selectin and Mac-1 molecules. J Immunol 1995;154:2291-2302. 
72. Furukawa Y, Umemoto E, Jang MH, Tohya K, Miyasaka M, Hirata T. Identification of novel 
isoforms of mouse L-selectin with different carboxyl-terminal tails. J Biol Chem 2008;283:12112-
12119. 
73. Ivetic A, Ridley AJ. The telling tail of L-selectin. Biochem Soc Trans 2004;32:1118-1121. 
74. Simon SI, Cherapanov V, Nadra I, Waddell TK, Seo SM, Wang Q, et al. Signaling functions of L-
selectin in neutrophils: alterations in the cytoskeleton and colocalization with CD18. J Immunol 
1999;163:2891-2901. 
75. Blanks JE, Moll T, Eytner R, Vestweber D. Stimulation of P-selectin glycoprotein ligand-1 on 
mouse neutrophils activates beta 2-integrin mediated cell attachment to ICAM-1. Eur J Immunol 
1998;28:433-443. 
25 
 
76. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-
selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. 
Signal integration and NF-kappa B translocation. J Clin Invest 1995;95:2297-2303. 
77. Wang HB, Wang JT, Zhang L, Geng ZH, Xu WL, Xu T, et al. P-selectin primes leukocyte integrin 
activation during inflammation. Nat Immunol 2007;8:882-892. 
78. Evangelista V, Pamuklar Z, Piccoli A, Manarini S, Dell'elba G, Pecce R, et al. Src family kinases 
mediate neutrophil adhesion to adherent platelets. Blood 2007;109:2461-2469. 
79. Urzainqui A, Serrador JM, Viedma F, Yanez-Mo M, Rodriguez A, Corbi AL, et al. ITAM-based 
interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor 
PSGL-1. Immunity 2002;17:401-412. 
80. Snapp KR, Heitzig CE, Kansas GS. Attachment of the PSGL-1 cytoplasmic domain to the actin 
cytoskeleton is essential for leukocyte rolling on P-selectin. Blood 2002;99:4494-4502. 
81. Zarbock A, Abram CL, Hundt M, Altman A, Lowell CA, Ley K. PSGL-1 engagement by E-selectin 
signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow 
leukocyte rolling. J Exp Med 2008;205:2339-2347. 
82. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-885. 
83. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in 
facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as 
enhancers of metastasis. Proc Natl Acad Sci U S A 2002;99:2193-2198. 
84. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and 
metastasis. Proc Natl Acad Sci U S A 1998;95:9325-9330. 
85. Läubli H, Stevenson JL, Varki A, Varki NM, Borsig L. L-selectin facilitation of metastasis involves 
temporal induction of fut7-dependent ligands at sites of tumor cell arrest. Cancer Res 
2006;66:1536-1542. 
86. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. 
Thromb Res 2001;102:V215-V224. 
87. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable 
molecular explanation for the association of Trousseau syndrome with mucinous 
adenocarcinomas. J Clin Invest 2003;112:853-862. 
88. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P. Rapid induction of 
cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res 
1999;59:1356-1361. 
89. Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA. Liver endothelial E-
selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 
1997;71:612-619. 
90. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl 
Lewis A expression-The Warburg effect revisited. Glycoconj J 2004;20:353-364. 
26 
 
91. Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and 
organ selectivity of metastasis. Clin Exp Metastasis 2008;25:335-344. 
92. Burdick MM, McCaffery JM, Kim YS, Bochner BS, Konstantopoulos K. Colon carcinoma cell 
glycolipids, integrins, and other glycoproteins mediate adhesion to HUVECs under flow. Am J 
Physiol Cell Physiol 2003;284:C977-987. 
93. Mannori G, Santoro D, Carter L, Corless C, Nelson RM, Bevilacqua MP. Inhibition of colon 
carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol 1997;151:233-
243. 
94. Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, et al. A peptide mimic of 
E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res 
2000;60:450-456. 
95. Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, et al. Alpha 1,3 
fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U 
S A 2009;106:19491-19496. 
96. Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, et al. Differential colon 
cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res 
1995;55:4425-4431. 
97. Aychek T, Miller K, Sagi-Assif O, Levy-Nissenbaum O, Israeli-Amit M, Pasmanik-Chor M, et al. E-
selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 
release. Int J Cancer 2008;123:1741-1750. 
98. Laferriere J, Houle F, Taher MM, Valerie K, Huot J. Transendothelial migration of colon carcinoma 
cells requires expression of E-selectin by endothelial cells and activation of stress-activated 
protein kinase-2 (SAPK2/p38) in the tumor cells. J Biol Chem 2001;276:33762-33772. 
99. Tremblay PL, Auger FA, Huot J. Regulation of transendothelial migration of colon cancer cells by 
E-selectin-mediated activation of p38 and ERK MAP kinases. Oncogene 2006. 
100. Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. Redirection of tumor metastasis by 
expression of E-selectin in vivo. J Exp Med 1996;183:581-587. 
101. Läubli H, Borsig L. Selectins as mediators of lung metastasis. Cancer Microenviron 2010;3:in 
press. 
102. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer 
Metastasis Rev 1992;11:325-351. 
103. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 
1981;95:636-641. 
104. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3:425-430. 
105. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor 
interaction in vitro and metastasis formation in vivo. J Clin Invest 1988;81:1012-1019. 
106. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis 
Rev 1984;3:99-114. 
27 
 
107. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-
activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004;104:397-401. 
108. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: 
mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. 
Proc Natl Acad Sci U S A 2001;98:3352-3357. 
109. Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, et al. Endothelial P-selectin as a 
target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004;64:2743-
2750. 
110. Qian F, Hanahan D, Weissman IL. L-selectin can facilitate metastasis to lymph nodes in a 
transgenic mouse model of carcinogenesis. Proc Natl Acad Sci U S A 2001;98:3976-3981. 
111. Aviram R, Raz N, Kukulansky T, Hollander N. Expression of L-selectin and efficient binding to 
high endothelial venules do not modulate the dissemination potential of murine B-cell lymphoma. 
Cancer Immunol Immunother 2001;50:61-68. 
112. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-
444. 
113. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-
252. 
114. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867. 
115. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002;70:498-505. 
116. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates 
metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009;4:e6562. 
117. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-2823. 
118. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-456. 
119. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: 
Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10:355-362. 
120. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble 
P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna 
Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-2708. 
121. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 
2009;6:339-351. 
122. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor 
cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 
2005;23:1420-1430. 
123. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells 
promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992;89:11832-11836. 
124. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 
2006;32 Suppl 1:61-68. 
28 
 
125. Clezardin P, Drouin J, Morel-Kopp MC, Hanss M, Kehrel B, Serre CM, et al. Role of platelet 
membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet 
aggregation induced by human osteosarcoma cells. Cancer Res 1993;53:4695-4700. 
126. Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E. Characterization of 
tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by 
MCF-7 breast cancer cells. Thromb Res 1995;79:261-274. 
127. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, et al. Multiple roles for platelet GPIIb/IIIa 
and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 
2002;62:2824-2833. 
128. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in 
mice is impeded by platelets. Cancer Res 1999;59:1295-1300. 
129. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Tumor 
cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic 
potential through natural killer cell-dependent and-independent mechanisms. Blood 
2007;110:133-141. 
130. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during 
platelet activation mediates aggregation. Nature 1997;386:616-619. 
131. Belloc C, Lu H, Soria C, Fridman R, Legrand Y, Menashi S. The effect of platelets on 
invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995;60:413-
417. 
132. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al. Platelet-
derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast 
cancer. J Clin Invest 2004;114:1714-1725. 
133. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, et al. IL-18 
regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-
1. Proc Natl Acad Sci U S A 2000;97:734-739. 
134. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al. Serum levels of E-
selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological 
features, patient survival and tumour surgery. Eur J Cancer 2001;37:2392-2397. 
135. Matsuo Y, Amano S, Furuya M, Namiki K, Sakurai K, Nishiyama M, et al. Involvement of p38alpha 
mitogen-activated protein kinase in lung metastasis of tumor cells. J Biol Chem 2006;281:36767-
36775. 
136. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell 
adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer 
Res 2000;60:3978-3984. 
137. Auguste P, Fallavollita L, Wang N, Burnier J, Bikfalvi A, Brodt P. The host inflammatory response 
promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 
2007;170:1781-1792. 
29 
 
138. Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin 
to promote breast cancer metastasis to lung and bone. J Biol Chem 2009;284:29087-29096. 
139. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer 
Res 2006;66:605-612. 
140. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and 
promotion of malignant disease. Cancer Cell 2005;7:211-217. 
141. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of 
chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 
2006;8:1369-1375. 
142. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by 
vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 
2002;2:289-300. 
143. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive 
haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-
827. 
144. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in 
inflammation and cancer. Expert Opin Ther Targets 2007;11:1473-1491. 
145. Marathe DD, Buffone A, Jr., Chandrasekaran EV, Xue J, Locke RD, Nasirikenari M, et al. 
Fluorinated per-acetylated GalNAc metabolically alters glycan structures on leukocyte PSGL-1 
and reduces cell binding to selectins. Blood 2010;115:1303-1312. 
146. Fuster MM, Brown JR, Wang L, Esko JD. A disaccharide precursor of sialyl Lewis X inhibits 
metastatic potential of tumor cells. Cancer Res 2003;63:2775-2781. 
147. Brown JR, Fuster MM, Li R, Varki N, Glass CA, Esko JD. A disaccharide-based inhibitor of 
glycosylation attenuates metastatic tumor cell dissemination. Clin Cancer Res 2006;12:2894-
2901. 
148. Eppihimer MJ, Schaub RG. Soluble P-selectin antagonist mediates rolling velocity and adhesion 
of leukocytes in acutely inflamed venules. Microcirculation 2001;8:15-24. 
149. Scalia R, Armstead VE, Minchenko AG, Lefer AM. Essential role of P-selectin in the initiation of 
the inflammatory response induced by hemorrhage and reinfusion. J Exp Med 1999;189:931-938. 
150. Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, Schultz JE, et al. Efomycine M, a new 
specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. 
Nat Med 2002;8:366-372. 
151. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. Selectins--potential pharmacological targets? 
Drug Discov Today 2006;11:1034-1040. 
152. Bock D, Philipp S, Wolff G. Therapeutic potential of selectin antagonists in psoriasis. Expert Opin 
Investig Drugs 2006;15:963-979. 
153. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 
2002;1:140-148. 
30 
 
154. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and 
heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated 
and low molecular weight heparins as therapeutic agents. J Clin Invest 1998;101:877-889. 
155. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of 
heparins--correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 
2005;11:7003-7011. 
156. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R, et al. The ability of 
different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory 
capacity on bloodborne metastasis in vivo. Thromb Haemost 2006;95:535-540. 
157. Borsig L. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates 
metastasis. Semin Thromb Hemost 2007;33:540-546. 
158. Casu B, Vlodavsky I, Sanderson RD. Non-anticoagulant heparins and inhibition of cancer. 
Pathophysiol Haemost Thromb 2008;36:195-203. 
159. Hostettler N, Naggi A, Torri G, Casu B, Vlodavsky I, Borsig L. P-selectin- and heparanase-
dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007;21:3562-3572. 
160. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on 
cancer and cancer survival. J Clin Oncol 2009;27:4902-4911. 
161. Varki NM, Varki A. Heparin Inhibition of Selectin-Mediated Interactions during the Hematogenous 
Phase of Carcinoma Metastasis: Rationale for Clinical Studies in Humans. Semin Thromb Hemost 
2002;28:53-66. 
162. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by 
circulating cancer cells. Cell 2009;139:1315-1326. 
 
 
31 
 
Figure legends: 
Figure 1 Selectin-mediated interaction in health and during cancer metastasis. 
a) Selectins mediate initial interactions leading to adhesion of leukocytes and platelets to 
sites of locally activated endothelium often at sites of acute or chronic inflammation.  
b) Potential interactions that occur between selectins and cancer cells during 
hematogeneous metastasis. All interactions have been shown to occur in vivo. While 
multiple interactions are possible, the temporal and spatial presence of selectins 
determines their contribution to metastasis. Potential role of selectins in metastasis: 1 – 
L-selectin mediates the recruitment of leukocytes to cancer cells, and L-selectin-
mediated activation of leukocytes may be expected. Whether L-selectin mediates a 
direct contact between leukocytes and cancer cells remains to be determined. 2 – 
Platelet-cancer cell interactions are primarily mediated by P-selectin, and platelet 
aggregates. Thereby platelets protect cancer cells from the innate immune system and 
contribute to the means by which cancer cells adhere to and/or mechanistically arrest in 
the microvasculature. 3 – Adhesion of cancer cells to activated endothelium has been 
well described primarily in vitro. E- and P-selectin involvement in cancer cell adhesion to 
endothelium indicates a pro-metastatic function for activated endothelium in vivo. The 
mechanism leading to specific expression of E-selectin in distant organs remains to be 
defined. 
 
Figure 2 Selectins support tissue colonization by mediating heterotypic 
interactions within the metastatic microenvironment and the formation of a 
metastatic niche 
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a) Cancer cells from primary lesions reach blood vessels either directly or through lymph 
vessels. Intravasated cancer cells circulate until they become arrested in the 
microvasculature of distant organs. b) During circulation or after microvascular arrest, a 
tumor embolus is formed by P-selectin mediated interactions of tumor cells (TC) with 
platelets (minutes-hours after intravasation). The micrograph shows MC-38 tumor cells 
(grey) arrested in the pulmonary microvasculature 30 minutes after intravenous injection 
of tumor cells. Aggregates of platelets (red, CD41) are observed around the tumor cells.  
Nuclei are blue. EC, endothelial cells.  c) Tumor embolus formation and intravascular 
arrest leads to the subsequent inflammatory activation of the metastatic 
microenvironment, including activation of endothelial cells (aEC) and recruitment of 
myeloid cells (MC) including neutrophils and monocytes (hours-days). Leukocyte 
recruitment depends partially on L-selectin and the expression of FucT VII dependent 
selectin ligands on activated endothelial cells. Moreover, endothelial P-selectin and E-
selectin could be implicated in leukocyte recruitment. Selectin-mediated interactions 
contribute to local chemokine production that enhances inflammatory activation of the 
microenvironment. The micrograph shows myeloid cells (CD11b, green and Gr1, red 
positive cells) within the pulmonary microenvironment of intravenously injected MC-38 
tumor cells (grey) during early lung colonization. Nuclei are blue. d) Inflammatory 
activation of the metastatic microenvironment partially mediated by selectins generates 
a metastatic niche, wherein tumor cells can survive, extravasate, proliferate and 
eventually form new metastatic lesions. The micrograph shows the growing edge of a 
metastatic lesion; tumor cells (green), F4/80 positive cells (red), nuclei (blue). From 
metastatic lesions, cancer cells can again intravasate and disseminate to other organs 
or the primary lesion [162]. 
33 
 
 
 
34 
 
 
